Search
The lungs represent a key interface between the body and the environment.
As part of our research development and planning we invite members of the community to work with us. Click here to find out how.
News & Events
National funding for bright ideas targeting ear infections and dangerous fungiTwo projects led by The Kids Research Institute Australia have been awarded more than $2.5 million to fund innovative ideas focused, respectively, on combating persistent ear infections and investigating how dangerous fungi invade the bodies of immunocompromised people.
News & Events
The Kids researchers named finalists in 2024 Premier’s Science AwardsFive The Kids Research Institute Australia researchers and a popular Institute-led science festival for kids have been named as finalists in the 2024 Premier’s Science Awards.
News & Events
The Kids Research Institute Australia welcomes world-leading new laws for vapesThe Kids Research Institute Australia welcomes the Federal Government's stringent vaping reforms that took effect on 1 July 2024.
News & Events
The Kids respiratory researcher wins prestigious prize at 2021 Premier’s Science AwardsThe Kids Research Institute Australia researcher, Niamh Troy, has been named a joint winner of the Exxon Mobile Student Scientist of the Year award at the Premier’s Science Awards.
Research
Cohort profile: The WAACHS Linked Data StudyDespite the volume of accumulating knowledge from prospective Aboriginal cohort studies, longitudinal data describing developmental trajectories in health and well-being is limited.
Research
Improving screening in a paediatric cohort for cystic fibrosis-related diabetes: A quality improvement projectAndré Schultz MBChB, PhD, FRACP Program Head, Respiratory Health RFA Program Head, Respiratory Health RFA Prof André Schultz is the Program Head of
Research
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trialRepurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this trial was to assess the effectiveness of affordable, widely available, repurposed drugs used in combination for treatment of COVID-19, which may be particularly relevant to low-resource countries.
Research
Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?For those born with cystic fibrosis (CF), hyper-concentrated mucus with a dysfunctional structure significantly impacts CF airways, providing a perfect environment for bacterial colonization and subsequent chronic infection. Early treatment with antibiotics limits the prevalence of bacterial pathogens but permanently alters the CF airway microenvironment, resulting in antibiotic resistance and other long-term consequences.